Indications and Donor Selections for Allogeneic Stem Cell Transplantation in Children with Hematologic Malignancies

Pediatric Clinics of North America

Volumn 55, Issue 1, 2008, Pages 71-96

  Handgretinger, Rupert ^a   Kurtzberg, Joanne ^b   Egeler, R Maarten ^c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; HLA ANTIBODY; MELPHALAN; PREDNISONE; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DONOR SELECTION; DRUG DOSE REDUCTION; DRUG RESPONSE; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HLA SYSTEM; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMIA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PROGNOSIS; RADIATION DOSE; RECURRENCE RISK; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REVIEW; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE; UMBILICAL CORD BLOOD; WHOLE BODY RADIATION;

CHILD; GRAFT SURVIVAL; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 38649108802     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2007.10.013     Document Type: Review

References (148)

1. Pui C.H., Campana D., and Evans W.E. Childhood acute lymphoblastic leukaemia-current status and future perspectives. Lancet Oncol 2 (2001) 597-607
2. Pui C.H., and Evans W.E. Treatment of acute lymphoblastic leukemia. N Engl J Med 354 (2006) 166-178
3. Gaynon P.S., Qu R.P., Chappell R.J., et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse-the Children's Cancer Group Experience. Cancer 82 (1998) 1387-1395
4. Johansson B., Moorman A.V., Haas O.A., et al. Hematologic malignancies with t(4;11)(q21;q23)-a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. European 11q23 Workshop participants. Leukemia 12 (1998) 779-787
5. Heerema N.A., Nachman J.B., Sather H.N., et al. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 94 (1999) 4036-4045
6. Nachman J.B., Heerema N.A., Sather H., et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110 (2007) 1112-1115
7. Sandlund J.T., Harrison P.L., Rivera G., et al. Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood 100 (2002) 43-47
8. Coustan-Smith E., Sancho J., Behm F.G., et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 100 (2002) 52-58
9. Arico M., Valsecchi M.G., Camitta B., et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342 (2000) 998-1006
10. Balduzzi A., Valsecchi M.G., Uderzo C., et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 366 (2005) 635-642
11. Schrauder A., Reiter A., Gadner H., et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol 24 (2006) 5742-5749
12. Satwani P., Sather H., Ozkaynak F., et al. Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: a Children's Oncology Group study report. Biol Blood Marrow Transplant 13 (2007) 218-227
13. Peters C., Schrauder A., Schrappe M., et al. Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM/IBFM/EBMT concepts. Bone Marrow Transplant 35 Suppl 1 (2005) S9-S11
14. Schrappe M., Reiter A., Zimmermann M., et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia 14 (2000) 2205-2222
15. Chessells J.M. Relapsed lymphoblastic leukaemia in children: a continuing challenge. Br J Haematol 102 (1998) 423-438
16. Chessells J.M., Veys P., Kempski H., et al. Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol 123 (2003) 396-405
17. Borgmann A., von S.A., Hartmann R., et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 101 (2003) 3835-3839
18. Roy A., Cargill A., Love S., et al. Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial. Br J Haematol 130 (2005) 67-75
19. Einsiedel H.G., von S.A., Hartmann R., et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. J Clin Oncol 23 (2005) 7942-7950
20. Rivera G.K., Zhou Y., Hancock M.L., et al. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer 103 (2005) 368-376
21. Eapen M., Raetz E., Zhang M.J., et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 107 (2006) 4961-4967
22. Gaynon P.S., Harris R.E., Altman A.J., et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. J Clin Oncol 24 (2006) 3150-3156
23. Matsuzaki A., Nagatoshi Y., Inada H., et al. Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation-a report from the Kyushu-Yamaguchi Children's Cancer Study Group. Pediatr Blood Cancer 45 (2005) 111-120
24. Rizzari C., Valsecchi M.G., Arico M., et al. Outcome of very late relapse in children with acute lymphoblastic leukemia. Haematologica 89 (2004) 427-434
25. Eckert C., Biondi A., Seeger K., et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 358 (2001) 1239-1241
26. Coustan-Smith E., Gajjar A., Hijiya N., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 18 (2004) 499-504
27. Knechtli C.J., Goulden N.J., Hancock J.P., et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 92 (1998) 4072-4079
28. Bader P., Hancock J., Kreyenberg H., et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 16 (2002) 1668-1672
29. van der Velden V.H., Joosten S.A., Willemse M.J., et al. Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia 15 (2001) 1485-1487
30. Krejci O., van der Velden V.H., Bader P., et al. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. Bone Marrow Transplant 32 (2003) 849-851
31. Imashuku S., Terui K., Matsuyama T., et al. Lack of clinical utility of minimal residual disease detection in allogeneic stem cell recipients with childhood acute lymphoblastic leukemia: multi-institutional collaborative study in Japan. Bone Marrow Transplant 31 (2003) 1127-1135
32. Sramkova L., Muzikova K., Fronkova E., et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 48 (2007) 93-100
33. Pui C.H., Behm F.G., Downing J.R., et al. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 12 (1994) 909-915
34. Pui C.H., Gaynon P.S., Boyett J.M., et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359 (2002) 1909-1915
35. Triplett B., Handgretinger R., Pui C.H., et al. KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia. Blood 107 (2006) 1238-1239
36. Stevens R.F., Hann I.M., Wheatley K., et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 101 (1998) 130-140
37. Creutzig U., Ritter J., Zimmermann M., et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. J Clin Oncol 19 (2001) 2705-2713
38. Krance R.A., Hurwitz C.A., Head D.R., et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 19 (2001) 2804-2811
39. Wells R.J., Arthur D.C., Srivastava A., et al. Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 16 (2002) 601-607
40. Creutzig U., Zimmermann M., Ritter J., et al. Definition of a standard-risk group in children with AML. Br J Haematol 104 (1999) 630-639
41. Wheatley K., Burnett A.K., Goldstone A.H., et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 107 (1999) 69-79
42. Dastugue N., Payen C., Lafage-Pochitaloff M., et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia 9 (1995) 1491-1498
43. Raimondi S.C., Chang M.N., Ravindranath Y., et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a Cooperative Pediatric Oncology Group study-POG 8821. Blood 94 (1999) 3707-3716
44. Chen A.R., Alonzo T.A., Woods W.G., et al. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?-an American view. Br J Haematol 118 (2002) 378-384
45. Creutzig U., and Reinhardt D. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?-a European view. Br J Haematol 118 (2002) 365-377
46. Amadori S., Testi A.M., Arico M., et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. J Clin Oncol 11 (1993) 1046-1054
47. Nesbit Jr. M.E., Buckley J.D., Feig S.A., et al. Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 12 (1994) 127-135
48. Ravindranath Y., Yeager A.M., Chang M.N., et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 334 (1996) 1428-1434
49. Woods W.G., Neudorf S., Gold S., et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 97 (2001) 56-62
50. Neudorf S., Sanders J., Kobrinsky N., et al. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 103 (2004) 3655-3661
51. Alonzo T.A., Wells R.J., Woods W.G., et al. Postremission therapy for children with acute myeloid leukemia: the Children's Cancer Group experience in the transplant era. Leukemia 19 (2005) 965-970
52. Burnett A.K., Wheatley K., Goldstone A.H., et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 118 (2002) 385-400
53. Handgretinger R., Chen X., Pfeiffer M., et al. Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation. Ann N Y Acad Sci 1106 (2007) 279-289 Epub 2007 Apr 18
54. Willemze A.J., Geskus R.B., Noordijk E.M., et al. HLA-identical haematopoietic stem cell transplantation for acute leukaemia in children: less relapse with higher biologically effective dose of TBI. Bone Marrow Transplant 40 (2007) 319-327
55. Neudorf S., Sanders J., Kobrinsky N., et al. Autologous bone marrow transplantation for children with AML in first remission. Bone Marrow Transplant 40 (2007) 313-318
56. Goulden N., Virgo P., and Grimwade D. Minimal residual disease directed therapy for childhood acute myeloid leukaemia: the time is now. Br J Haematol 134 (2006) 273-282
57. Webb D.K., Wheatley K., Harrison G., et al. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia 13 (1999) 25-31
58. Stahnke K., Boos J., der-Gotze C., et al. Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia 12 (1998) 1534-1538
59. Aladjidi N., Auvrignon A., Leblanc T., et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 21 (2003) 4377-4385
60. Wells R.J., Adams M.T., Alonzo T.A., et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol 21 (2003) 2940-2947
61. Johnston D.L., Alonzo T.A., Gerbing R.B., et al. Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol 23 (2005) 9172-9178
62. Abrahamsson J., Clausen N., Gustafsson G., et al. Improved outcome after relapse in children with acute myeloid leukaemia. Br J Haematol 136 (2007) 229-236
63. Nemecek E.R., Gooley T.A., Woolfrey A.E., et al. Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukemia. Bone Marrow Transplant 34 (2004) 799-806
64. Webb D.K. Management of relapsed acute myeloid leukaemia. Br J Haematol 106 (1999) 851-859
65. Meshinchi S., Leisenring W.M., Carpenter P.A., et al. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biol Blood Marrow Transplant 9 (2003) 706-713
66. Luger S., and Sacks N. Bone marrow transplantation for myelodysplastic syndrome-who? when? and which?. Bone Marrow Transplant 30 (2002) 199-206
67. Kardos G., Baumann I., Passmore S.J., et al. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 102 (2003) 1997-2003
68. Yoshimi A., Baumann I., Fuhrer M., et al. Immunosuppressive therapy with anti-thymocyte globulin and cyclosporine A in selected children with hypoplastic refractory cytopenia. Haematologica 92 (2007) 397-400
69. Strahm B., Locatelli F., Bader P., et al. Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Bone Marrow Transplant 40 (2007) 329-333
70. Chan G.C., Wang W.C., Raimondi S.C., et al. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count. Leukemia 11 (1997) 206-211
71. Hasle H., Arico M., Basso G., et al. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS). Leukemia 13 (1999) 376-385
72. Woods W.G., Barnard D.R., Alonzo T.A., et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J Clin Oncol 20 (2002) 434-440
73. Hasle H., Alonzo T.A., Auvrignon A., et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood 109 (2007) 4641-4647
74. Passmore S.J., Hann I.M., Stiller C.A., et al. Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood 85 (1995) 1742-1750
75. Heaney M.L., and Golde D.W. Myelodysplasia. N Engl J Med 340 (1999) 1649-1660
76. Anderson J.E., Appelbaum F.R., and Storb R. An update on allogeneic marrow transplantation for myelodysplastic syndrome. Leuk Lymphoma 17 (1995) 95-99
77. Sutton L., Chastang C., Ribaud P., et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood 88 (1996) 358-365
78. Davies S.M., Wagner J.E., Defor T., et al. Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia. Br J Haematol 96 (1997) 749-756
79. Anderson J.E., Anasetti C., Appelbaum F.R., et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 93 (1996) 59-67
80. Lutz P., Zix-Kieffer I., Souillet G., et al. Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC Children's Leukemia Cooperative Group (CLCG). Bone Marrow Transplant 18 (1996) 1111-1116
81. Castleberry R.P., Emanuel P.D., Zuckerman K.S., et al. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med 331 (1994) 1680-1684
82. Pui C.H., and Arico M. Isotretinoin for juvenile chronic myelogenous leukemia. N Engl J Med 332 (1995) 1520-1521
83. Locatelli F., Nollke P., Zecca M., et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 105 (2005) 410-419
84. Niemeyer C.M., Arico M., Basso G., et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood 89 (1997) 3534-3543
85. Locatelli F., Giorgiani G., and Comoli P. Allogeneic transplantation of haematopoietic progenitors for myelodysplastic syndromes and myeloproliferative disorders. Bone Marrow Transplant 21 Suppl 2 (1998) S17-S20
86. Manabe A., Okamura J., Yumura-Yagi K., et al. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia 16 (2002) 645-649
87. Passmore S.J., Chessells J.M., Kempski H., et al. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br J Haematol 121 (2003) 758-767
88. Smith F.O., King R., Nelson G., et al. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. Br J Haematol 116 (2002) 716-724
89. MacMillan M.L., Davies S.M., Orchard P.J., et al. Haemopoietic cell transplantation in children with juvenile myelomonocytic leukaemia. Br J Haematol 103 (1998) 552-558
90. Emanuel P.D., Snyder R.C., Wiley T., et al. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood 95 (2000) 639-645
91. Yoshimi A., Mohamed M., Bierings M., et al. Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia. Leukemia 21 (2007) 556-560
92. Dann E.J., and Rowe J.M. Biology and therapy of secondary leukaemias. Best Pract Res Clin Haematol 14 (2001) 119-137
93. Ballen K.K., and Antin J.H. Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes. Hematol Oncol Clin North Am 7 (1993) 477-493
94. Yakoub-Agha I., de La S.P., Ribaud P., et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French Society of Bone Marrow Transplantation. J Clin Oncol 18 (2000) 963-971
95. Barnard D.R., Lange B., Alonzo T.A., et al. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood 100 (2002) 427-434
96. Woodard P., Barfield R., Hale G., et al. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. Pediatr Blood Cancer 47 (2006) 931-935
97. Clift R.A., Appelbaum F.R., and Thomas E.D. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 82 (1993) 1954-1956
98. Cwynarski K., Roberts I.A., Iacobelli S., et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 102 (2003) 1224-1231
99. Dini G., Rondelli R., Miano M., et al. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children: experience of eight European countries. The EBMT Paediatric Diseases Working Party. Bone Marrow Transplant 18 Suppl 2 (1996) 80-85
100. Gamis A.S., Haake R., McGlave P., et al. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children. J Clin Oncol 11 (1993) 834-838
101. Millot F., Esperou H., Bordigoni P., et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant 32 (2003) 993-999
102. van R.F., Szydlo R.M., Hermans J., et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20 (1997) 553-560
103. Elmaagacli A.H., Basoglu S., Peceny R., et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 99 (2002) 1130-1135
104. Eapen M., Horowitz M.M., Klein J.P., et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 22 (2004) 4872-4880
105. Creutzig U., Ritter J., Zimmermann M., et al. Prognosis of children with chronic myeloid leukemia: a retrospective analysis of 75 patients. Klin Padiatr 208 (1996) 236-241 [in German]
106. Davies S.M., DeFor T.E., McGlave P.B., et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 110 (2001) 339-346
107. Barta A., Denes R., Masszi T., et al. Remarkably reduced transplant-related complications by dibromomannitol non-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia. Acta Haematol 105 (2001) 64-70
108. Chakraverty R., Peggs K., Chopra R., et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99 (2002) 1071-1078
109. Kolb H.J., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76 (1990) 2462-2465
110. Thornley I., Perentesis J.P., Davies S.M., et al. Treating children with chronic myeloid leukemia in the imatinib era: a therapeutic dilemma?. Med Pediatr Oncol 41 (2003) 115-117
111. Pulsipher M.A. Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?. Pediatr Blood Cancer 43 (2004) 523-533
112. Walz C., and Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 57 (2006) 145-164
113. Bunin N., Aplenc R., Kamani N., et al. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 32 (2003) 543-548
114. Davies S.M., Ramsay N.K., Klein J.P., et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 18 (2000) 340-347
115. Niederwieser D., Maris M., Shizuru J.A., et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101 (2003) 1620-1629
116. Or R., Shapira M.Y., Resnick I., et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101 2 (2003) 441-445
117. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 (1997) 4531-4536
118. Prasad V.K., Kernan N.A., Heller G., et al. DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. Blood 93 (1999) 399-409
119. Speiser D.E., Tiercy J.M., Rufer N., et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 87 (1996) 4455-4462
120. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104 (2004) 1923-1930
121. Chalandon Y., Tiercy J.M., Schanz U., et al. Impact of high-resolution matching in allogeneic unrelated donor stem cell transplantation in Switzerland. Bone Marrow Transplant 37 (2006) 909-916
122. Yakoub-Agha I., Mesnil F., Kuentz M., et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 24 (2006) 5695-5702
123. Petersdorf E.W. HLA matching in allogeneic stem cell transplantation. Curr Opin Hematol 11 (2004) 386-391
124. Sedlacek P., Formankova R., Keslova P., et al. Low mortality of children undergoing hematopoietic stem cell transplantation from 7 to 8/10 human leukocyte antigen allele-matched unrelated donors with the use of antithymocyte globulin. Bone Marrow Transplant 38 (2006) 745-750
125. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98 (2001) 2043-2051
126. Ljungman P., Brand R., Einsele H., et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 102 (2003) 4255-4260
127. Ljungman P., Perez-Bercoff L., Jonsson J., et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 91 (2006) 78-83
128. Eapen M., Rubinstein P., Zhang M.J., et al. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol 24 (2006) 145-151
129. Dahlke J., Kroger N., Zabelina T., et al. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant 37 (2006) 155-163
130. Hambach L., Spierings E., and Goulmy E. Risk assessment in haematopoietic stem cell transplantation: minor histocompatibility antigens. Best Pract Res Clin Haematol 20 (2007) 171-187
131. Bettens F., Passweg J., Gratwohl A., et al. Association of TNFd and IL-10 polymorphisms with mortality in unrelated hematopoietic stem cell transplantation. Transplantation 81 (2006) 1261-1267
132. Dickinson A.M., and Middleton P.G. Beyond the HLA typing age: genetic polymorphisms predicting transplant outcome. Blood Rev 19 (2005) 333-340
133. Mullighan C.G., and Petersdorf E.W. Genomic polymorphism and allogeneic hematopoietic transplantation outcome. Biol Blood Marrow Transplant 12 (2006) 19-27
134. Souillet G., Rey S., Bertrand Y., et al. Outcome of unrelated bone marrow donor searches in 174 children resulting in 45 patients transplanted in the HLA-matched and -mismatched situation. Bone Marrow Transplant 26 (2000) 31-43
135. Tiercy J.M., Nicoloso G., Passweg J., et al. The probability of identifying a 10/10 HLA allele-matched unrelated donor is highly predictable. Bone Marrow Transplant 40 (2007) 515-522
136. Eapen M., Rubinstein P., Zhang M.J., et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 369 (2007) 1947-1954
137. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105 (2005) 1343-1347
138. Gluckman E., Rocha V., Arcese W., et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 32 (2004) 397-407
139. Sawczyn K.K., Quinones R., Malcolm J., et al. Cord blood transplant in childhood ALL. Pediatr Blood Cancer 45 (2005) 964-970
140. Rocha V., Cornish J., Sievers E.L., et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 97 (2001) 2962-2971
141. Wall D.A., Carter S.L., Kernan N.A., et al. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. Biol Blood Marrow Transplant 11 (2005) 637-646
142. Henslee-Downey P.J., Abhyankar S.H., Parrish R.S., et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 89 (1997) 3864-3872
143. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23 (2005) 3447-3454
144. Handgretinger R., Klingebiel T., Lang P., et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 27 (2001) 777-783
145. Klingebiel T., Lang P., Schumm M., et al. Experiences with haploidentical stem cell transplantation in children with acute lymphoblastic leukemia. Pathol Biol (Paris) 53 (2005) 159-161
146. Larocca A., Piaggio G., Podesta M., et al. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica 91 (2006) 935-940
147. Feuchtinger T., Matthes-Martin S., Richard C., et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 134 (2006) 64-76
148. Passweg J.R., Koehl U., Uharek L., et al. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 19 (2006) 811-824